Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 6, 1996, Pages 363-371

  Killion, Jerald J ^a   Bucana, Corazon D ^a   Radinsky, Robert ^a   Dong, Zhongyun ^a   O'Reilly, Terry ^b   Bilbe, Graham ^b   Tarcsay, Lajos ^b   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CIBA GEIGY LTD   (Switzerland)

Author keywords

chemotherapy; intestinal epithelium; MTP PE

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; MESSENGER RNA; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; ENTEROPATHY; FEMALE; INTESTINE EPITHELIUM; INTESTINE MUCOSA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; MELANOMA CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SMALL INTESTINE;

EID: 0030458438     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1996.11.363     Document Type: Article

References (40)

1. Canellos G, Demetri GD. Myelosuppression and conventional chemotherapy: what price, what benefit? J Clin Oncol 1993,11:1-2
2. Chabner BA, Meyers CE, Clinical Pharmacology of Cancer Chemotherapy: In. VT DeVita Jr, Hellman S, and Rosenberg SA, eds Cancer, Principles and Practice of Oncology. Philadelphia: JB Lippincott Co, 1989:349-395.
3. Pizzo PA. Granulocytopenia and cancer therapy Past problems, current solutions and future challenges. Cancer 1989:54:2649-2661.
4. Ijiri K, Potten CS Response of intestinal cells of differing topographical and hierarchial status to ten cytotoxic drugs and five sources of radiation. Br J Cancer 1983;47:175-183.
5. Ehreke MJ, Cohen SA, Mihich E. Selective effects of adnamycin on murine host defense systems. Immunol Rev 1982,65.55-75.
6. Deitch EA, Berg R. Bacterial translocation from the gut: a mechanism of infection. J Burn Care Rehab 1987;8.475-483.
7. Berg RD Bacterial translocation from the gastrointestinal tracts of mice receiving immunosuppressive chemotherapeutic agents. Curr Microbiol 1983,8:285-292.
8. Damia G, Komschlies KL, Futami H, Back T, Gruys E, Longo DL, Keller JR, Ruscetti FW, Wiltrout RH. Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: Protection from hematological and nonhematological toxicities. Cancer Res 1996;52:4082-4089.
9. Tsuji-Takayama K, Harashima A, Tahata H, Izumi N, Nishida Y, Namba M, Okuda Y, Ohta T, Kurimoto M. IFN-γ in combination with IL-3 accelerates platelet recovery in mice with 5-fluorouracil-induced marrow aplasia. J Interferon Cytokine Res 1996;16:447-451.
10. Crawford J, Ozer H, Stoller R, et al Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patents with small-cell lung cancer. N Engl J Med 1991;164.
11. Morstyn G, Souza LM, Sheridan W, et al Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. The Lancet 1988.667-672.
12. Bronchud MH, How-ell A, Crowther D, et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989;60:121-125.
13. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium N Engl J Med 1988;318:1414-1422
14. Steward WP, Verweij J, Somers R, et al Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer soft tissue and bone sarcoma group. J Clin Oncol 1993;11 15-21
15. Killion JJ, Brown DR, Wilson MR, et al. Prevention of chemotherapy or x-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide Oncol Res 1994;6:357-364.
16. Fidler LT, Fogler WE, Tarcsay L, et al. Systemic activation of macrophages and treatment of cancer metastases by liposome containing hydrophilic or lipophilic muramyl dipeptide Immunopharmacology 1983;235-253.
17. Fidler IJ, Fogler WE, Brownbill AF, et al. Systemic activation of tumoncidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. J Immunol 1987;138:4509-4514.
18. Tanguay S, Bucana CD, Wilson MR, et al. In vivo modulation of macrophage tumoricidal activity by the oral administration of the liposome-encapsulated macrophage activator CGP 19835A. Cancer Res 1994;54:5882-5888.
19. Du XX, Doerschuk CM, Orazi A, et al. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 1994;83:33-37.
20. 2 by human blood monocytes subsequent to interaction with different bacteria-derived agents. Lymphokine Res 1990;9:449-463
21. Fujimaki W, Itoh K, An T, et al. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide Cancer Bioither 1993;8:307-318.
22. Asano T, Matsushima K, Kleinerman ES. Liposome-encapsulated muramyl tripeptide upregulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and posttranscriptional level Cancer Immunol Immunother 1994;38:16-22.
23. Asano T, McIntyre BW, Bednarczyk JL, et al. Liposomal muramyl tnpeptide upregulates adhesion molecules on the surface of human monocytes. Oncology Res, in press.
24. Bastion Y, Bosly A, Gisselbrecht C, et al. A randomized double-blind phase III study of filgrastim (recombinant human G-CSF) vs placebo during intensive induction chemotherapy in 55 to 69 year old patients (Pts) with poor prognosis aggressive non-Hodgkin's lymphoma (NHL). Blood 1993;82:143a.
25. Hughes WT, Armstrong D, Bodey GP, et al From the Infectious Diseases Society of America Guidelines for the Use of Antimicrobial Agents in Neutropemc Patients with Unexplained Fever. J Infect Dis 1990;616:381-396.
26. Baskerville A, Batter-Hatton D. Intestinal lesions induced experimentally by methotrexate. Br J Exp Pathol 1977;58:663-669.
27. Fidler IJ. Optimization and limitations of systemic treatment of murine melanoma metastasis with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol Immunother 1986;21:169-173.
28. Fidler IJ, Sone S, Fogler WE, et al. Eradication of spontaneous metastasis and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 1981;78:1680-1684.
29. Dinney CPN, Bucana CD, Utsugi T, et al. Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362. Cancer Res 1991;51:3741-3747.
30. MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome encapsulated muramyl tripeptide. J Natl Cancer Inst 1989;81:935-938.
31. Kleinerman ES, Raymond AK, Bucana CD, et al. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother 1992;34:211-220.
32. Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol 1991;9:259-267.
33. Kleinerman ES, Jia SF, Griffin J, et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol 1992;10:1310-1316.
34. Melissen PMB, van Vianen W, Rusbergen Y, et al. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamine in treatment of experimental Klebsiella pneumoniae infection. Infection Immun 1992;60:95-101.
35. Izbicki JR, Raedler C, Anke A, et al. Beneficial effect of liposome-encapsulated muramyl tripeptide in experimental septicemia in a porcine model. Infection and Immunity 1991;59:126-130
36. Risin D, Kleinerman ES, Umezuy A, et al. Impairment of lymphocytes in the tumor microenvironment and the effect of systemic immunotherapy with L-MTP-PE. Cancer Immunol Immunother 1995;40:57-64.
37. Galelli A, Charolot B, Phillips NC, et al. Induction of colony- stimulating activity in mice by injection of liposomes containing lipophilic muramyl peptide derivatives. Cancer Res 1989;49 810-815.
38. Moore MAS, Warren DJ. Synergy of interleukin-1 and granulocyte colony stimulating factor: in vivo stimulation of stem cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl A cad Sci USA 1987;84:7144-7148.
39. Hirano T, Akira S, Taga T, et al Biological and clinical aspects of interleukin-6. Immunology Today 1990; 9.137-141.
40. Killion JJ, Kleinerman ES, Wilson MR, et al. Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents. Oncol Res 1992,4:413-418